Ancilia Biosciences

About:

Ancilia Biosciences offers bacterial therapeutics that address the microbiome's viral components.

Top Investors: National Science Foundation, Metaplanet, Safar Partners, Spacecadet Ventures, PsyMed Ventures

Description:

Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.

Total Funding Amount:

$5.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)anciliabio.com

Founders:

Alexandra Sakatos, Matthew Cummings

Number of Employees:

1-10

Last Funding Date:

2024-07-17

IPO Status:

Private

Industries: